FDA Commissioner Marty Makary was behind a “short-lived request” last week to reject a rare disease drug application from KalVista (KALV), multiple agency sources told Senior Biopharma Correspondent Andrew Dunn of Endpoints News.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista trading resumes
- KalVista trading halted, volatility trading pause
- Positive Outlook on KalVista Pharmaceuticals’ Sebetralstat Approval Despite FDA Decision Delay
- Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay
- KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA